Oral CGRP inhibitor
Showing 1 - 25 of >10,000
Migraine Trial in United States (AXS-07 (meloxicam-rizatriptan))
Recruiting
- Migraine
- AXS-07 (meloxicam-rizatriptan)
-
Colton, California
- +18 more
Sep 19, 2022
Migraine, Episodic Migraine, Headache Trial in New York (Click Digital Therapeutic)
Recruiting
- Migraine
- +3 more
- Click Digital Therapeutic
-
New York, New YorkClick Therapeutics
Aug 15, 2023
Adenocarcinoma Esophagus, Locally Advanced Adenocarcinoma, Siewert Type I Adenocarcinoma of Esophagogastric Junction Trial
Not yet recruiting
- Adenocarcinoma Esophagus
- +3 more
- Vactosertib
- +2 more
- (no location specified)
Sep 13, 2023
NSCLC Trial in Omaha (PLB1004)
Not yet recruiting
- Non-Small Cell Lung Cancer
-
Omaha, NebraskaNebraska Cancer Specialists
Sep 19, 2023
Esophageal Achalasia Trial in Marseille, Montpellier, Nîmes (Protein pump inhibitor therapy systematically)
Recruiting
- Esophageal Achalasia
- Protein pump inhibitor therapy systematically
-
Marseille, France
- +3 more
Jun 2, 2023
Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, Endometrial Cancer Trial in Oklahoma City, Houston (AO-252)
Recruiting
- Triple Negative Breast Cancer
- +2 more
-
Oklahoma City, Oklahoma
- +1 more
Nov 13, 2023
Healthy Adults Trial in Dallas (Treatment A, Treatment B)
Not yet recruiting
- Healthy Adults
- Treatment A
- Treatment B
-
Dallas, TexasLabcorp Clinical Research Unit Inc
May 11, 2023
Melanoma Metastatic in the Brain Trial in Gainesville (CA-4948, Pembrolizumab)
Not yet recruiting
- Melanoma Metastatic in the Brain
-
Gainesville, FloridaUniversity of Florida
Dec 20, 2022
Sjogren's Syndrome Trial run by the National Institute of Dental and Craniofacial Research (NIDCR) (tofacitinib, Placebo)
Recruiting
- Sjogren's Syndrome
- tofacitinib
- Placebo
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Nov 24, 2022
Cholangiocarcinoma Metastatic Trial in China (TT-00420 (tinengotinib))
Not yet recruiting
- Cholangiocarcinoma Metastatic
- TT-00420 (tinengotinib)
-
Guangzhou, Guangdong, China
- +6 more
Sep 26, 2023
Glucose Metabolism Disorders, Diabetes, Type 2, Hypoglycemic Agents Trial in Karachi (Empagliflozin 10 MG,
Recruiting
- Glucose Metabolism Disorders
- +3 more
- Empagliflozin 10 MG
- Insulin+Metformin+DPP4 inhibitor (DPP4I)
-
Karachi, PakistanSINA Shireen Jinnah colony
Nov 28, 2023
Arteriosclerosis, Hypercholesterolaemia Trial (MK-0616, Placebo)
Not yet recruiting
- Arteriosclerosis
- Hypercholesterolaemia
- MK-0616
- Placebo
- (no location specified)
Aug 17, 2023
AORTIC VALVE DISEASES, Thromboembolism Trial in Korea, Republic of (Rivaroxaban Oral Tablet, Vitamin K antagonist(warfarin))
Recruiting
- AORTIC VALVE DISEASES
- Thromboembolism
- Rivaroxaban Oral Tablet
- Vitamin K antagonist(warfarin)
-
Bucheon, Korea, Republic of
- +8 more
Oct 11, 2022
Neoadjuvant Chemoimmunotherapy in Resectable Locally Advanced
Completed
- Oral Cancer
- PD-1 inhibitor+carboplatin+albumin-bound paclitaxel
-
Guangzhou, Guangdong, ChinaSun Yat-Sen Memorial Hospital
Nov 20, 2023
Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma Trial in Boston (CB-103,
Not yet recruiting
- Adenoid Cystic Carcinoma
- +2 more
- CB-103
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Mar 14, 2023
Hypercholesterolemia, Familial Hypercholesterolemia Trial (MK-0616, Placebo)
Not yet recruiting
- Hypercholesterolemia
- Familial Hypercholesterolemia
- MK-0616
- Placebo
- (no location specified)
Jul 10, 2023
Hypercholesterolemia, Familial Hypercholesterolemia Trial (MK-0616, Placebo)
Not yet recruiting
- Hypercholesterolemia
- Familial Hypercholesterolemia
- MK-0616
- Placebo
- (no location specified)
Jul 10, 2023
Drug Drug Interaction Trial in Porto (Givinostat, Clarithromycin)
Completed
- Drug Drug Interaction
-
Porto, PortugalHospital da Prelada, 3rd Floor & East Wing 4th Floor Rua Sarment
Apr 26, 2023
Sudden Sensorineural Hearing Loss Trial (Statin, methylprednisolone, dexamethasone)
Not yet recruiting
- Sudden Sensorineural Hearing Loss
- Statin
- +3 more
- (no location specified)
Feb 2, 2023
Coagulation Disorder Trial (PROTHROMPLEX TOTAL, 4F-PCC)
Not yet recruiting
- Coagulation Disorder
- PROTHROMPLEX TOTAL
- 4F-PCC
- (no location specified)
Jul 14, 2022
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II Trial (PHA-022121 low dose, PHA-022121 medium
Recruiting
- Hereditary Angioedema
- +11 more
- PHA-022121 low dose
- +3 more
-
Birmingham, Alabama
- +7 more
Dec 5, 2022